A national pharmaceutical industry group headquartered in Shanghai
Shanghai Pharmaceutical Group Corporation Limited (the Company) (HKSE stock code: 02607; SSE stock code: 601607) is a national pharmaceutical industry group headquartered in Shanghai. The Company's main business covers pharmaceutical research and development and manufacturing, distribution and retailing, with an operating income of 105.5 billion yuan in 2015, the Company's overall ranking is among the best in China, and it is one of the few listed pharmaceutical companies in China with a leading position in both the pharmaceutical products and distribution markets, selected as a sample stock of the SSE 180 Index and the CSI 300 Index, and its H shares are selected as a constituent stock of the Hang Seng Index, a constituent stock of the Morgan Stanley China Index ( (MSCI).
Xuancheng, Anhui: the upper limit of the unified provident fund loan is 500000 yuan, and the number of talents is increased by 100000 yuan
The suggested retail price of all models of Volkswagen brand will be increased: the price of new energy models will be increased by 3000 yuan to 5000 yuan
361 degrees announced that the retail sales of main brand products in the first quarter recorded a high double-digit growth year-on-year.
Shanghai Pharmaceutical: the application for non-public offering of a shares was approved by the CSRC
2022 China AI Health 30 Report
Shanghai Pharmaceutical: Methotrexate tablets pass the consistency evaluation of generic drugs
Shanghai Pharmaceutical announcement that amiodarone hydrochloride tablets passed the consistency evaluation of generic drugs.
Shanghai Pharmaceutical: the subsidiary amiodarone hydrochloride injection was approved for production
Yiming food: the subsidiary is licensed to use the logo of Jiangsu student drinking milk
Jujie micro fiber: the net profit in 2021 will increase by 365% - 502% year-on-year
Financial Associated Press, January 11 - CNOOC expects a net output of 600 to 610 million barrels of oil equivalent in 2022.
Dingsheng new material: it is proposed to temporarily supplement working capital with idle raised funds of no more than 170 million yuan
HastenPharma Secures USD 315 Mn in Financing to Focus on M&A Business and R&D
Anhui-based biopharmaceutical company HastenPharma(海森生物) raised USD 315 million in funding on April 20, with the financing round aimed at focusing on future mergers and acquisitions and product innovation, according to EqualOcean.
Apr 23, 2023 12:20 PM
The revised version of the detailed rules of the standards for the audit of network short video content was released
Kaisheng new material: at present, thionyl chloride is basically in full production and full sales
Fitch confirmed that Wanzhou International, the parent company of Shuanghui, is rated as' BBB + 'with a stable outlook.
Minde Electronics: it is planned to raise no more than 500 million yuan